Identifying activating mutations in the EGFR gene: Prognostic and therapeutic implications in non-small cell lung cancer;Identificação de mutações ativadoras no gene EGFR: Implicações no prognóstico e no tratamento do carcinoma pulmonar de células não pequenas

Jornal Brasileiro de Pneumologia

Volumn 41, Issue 4, 2015, Pages 365-375

  Lopes, Gabriel Lima ^a   Vattimo, Edoardo Filippo de Queiroz ^b   de Castro Junior, Gilberto ^b  

^a HOSPITAL SÍRIO LIBANÊS   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Epidermal growth factor; Lung neoplasms drug therapy; Molecular targeted therapy; Mutation; Oncogenes; Receptor

Indexed keywords

AFATINIB; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; GENETIC MARKER; QUINAZOLINE DERIVATIVE;

ANTAGONISTS AND INHIBITORS; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE FREE SURVIVAL; DNA SEQUENCE; GENE DELETION; GENETIC MARKER; GENETICS; HUMAN; LUNG NEOPLASMS; MUTATION; PROGNOSIS; PROTO ONCOGENE; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE-FREE SURVIVAL; ERLOTINIB HYDROCHLORIDE; GENE DELETION; GENES, ERBB-1; GENETIC MARKERS; HUMANS; LUNG NEOPLASMS; MUTATION; PROGNOSIS; QUINAZOLINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTOR, EPIDERMAL GROWTH FACTOR; SEQUENCE ANALYSIS, DNA;

EID: 84941910206     PISSN: 18063713     EISSN: 18063756     Source Type: Journal    
DOI: 10.1590/S1806-37132015000004531     Document Type: Review

References (75)

1. Ministério da Saúde. Instituto Nacional do Câncer José Alencar Gomes da Silva [homepage on the Internet]. Rio de Janeiro: INCA [cited 2014 Nov 26]. Estimativa 2014 - Incidência de Câncer no Brasil 2014. [Adobe Acrobat document, 126p.]. Available from: http://www.inca.gov.br/estimativa/2014/estimativa-24012014.pdf
2. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [monograph on the Internet]. Lyon, France: International Agency for Research on Cancer; 2013 [cited 2015 Mar 23]. Available from: http://globocan.iarc.fr
3. Guimarães RM, Santos TS. Mortality distribution due to tracheal, lung, and bronchial cancer by gender, Brazil, 1980-2010. J Bras Pneumol. 2013;39(5):633-5. http://dx.doi.org/10.1590/S1806-37132013000500016
4. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002;346(2):92-8. http://dx.doi.org/10.1056/NEJMoa011954
5. Paez JG, Jänne PA, Lee JC, Tracy S, Greulich H, Gabriel S, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004;304(5676):1497-500. http://dx.doi.org/10.1126/science.1099314
6. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004;350(21):2129-39. http://dx.doi.org/10.1056/NEJMoa040938
7. Cohen S. The stimulation of epidermal proliferation by a specific protein (EGF). Dev Biol. 1965;12(3):394-407. http://dx.doi.org/10.1016/0012-1606(65)90005-9
8. Mendelsohn J, Baselga J. The EGF receptor family as targets for cancer therapy. Oncogene. 2000;19(56):6550-65. http://dx.doi.org/10.1038/sj.onc.1204082
9. Lemmon MA, Bu Z, Ladbury JE, Zhou M, Pinchasi D, Lax I, et al. Two EGF molecules contribute additively to stabilization of the EGFR dimer. EMBO J. 1997;16(2):281-94. http://dx.doi.org/10.1093/emboj/16.2.281
10. Downward J, Parker P, Waterfield MD. Autophosphorylation sites on the epidermal growth factor receptor. Nature. 1984;311(5985):483-5. http://dx.doi.org/10.1038/311483a0
11. van der Geer P, Pawson T. The PTB domain: a new protein module implicated in signal transduction. Trends Biochem Sci. 1995;20(7):277-80. http://dx.doi.org/10.1016/S0968-0004(00)89043-X
12. Seger R, Krebs EG. The MAPK signaling cascade. FASEB J. 1995;9(9):726-35.
13. Buday L, Downward J. Epidermal growth factor regulates p21ras through the formation of a complex of receptor, Grb2 adapter protein, and Sos nucleotide exchange factor. Cell. 1993;73(3):611-20. http://dx.doi.org/10.1016/0092-8674(93)90146-H
14. Fresno Vara JA, Casado E, de Castro J, Cejas P, Belda- Iniesta C, González-Barón M. PI3K/Akt signalling pathway and cancer. Cancer Treat Rev. 2004;30(2):193-204. http://dx.doi.org/10.1016/j.ctrv.2003.07.007
15. Downward J, Yarden Y, Mayes E, Scrace G, Totty N, Stockwell P, et al. Close similarity of epidermal growth factor receptor and v-erb-B oncogene protein sequences. Nature. 1984;307(5951):521-7. http://dx.doi.org/10.1038/307521a0
16. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol. 2001;2(2):127-37. http://dx.doi.org/10.1038/35052073
17. Cohen MH, Williams GA, Sridhara R, Chen G, McGuinn WD Jr, Morse D, et al. United States Food and Drug Administration Drug Approval summary: Gefitinib (ZD1839; Iressa) tablets. Clin Cancer Res. 2004;10(4):1212-8. http://dx.doi.org/10.1158/1078-0432.CCR-03-0564
18. Cohen MH, Johnson JR, Chen YF, Sridhara R, Pazdur R. FDA drug approval summary: erlotinib (Tarceva) tablets. Oncologist. 2005;10(7):461-6. http://dx.doi.org/10.1634/theoncologist.10-7-461
19. Dungo RT, Keating GM. Afatinib: first global approval. Drugs. 2013;73(13):1503-15. http://dx.doi.org/10.1007/s40265-013-0111-6
20. Baselga J, Albanell J. Epithelial growth factor receptor interacting agents. Hematol Oncol Clin North Am. 2002;16(5):1041-63. http://dx.doi.org/10.1016/S0889-8588(02)00055-2
21. Bianco C, Tortora G, Bianco R, Caputo R, Veneziani BM, Caputo R, et al. Enhancement of antitumor activity of ionizing radiation by combined treatment with the selective epidermal growth factor receptor-tyrosine kinase inhibitor ZD1839 (Iressa). Clin Cancer Res. 2002;8(10):3250-8.
22. Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douillard JY, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. J Clin Oncol. 2003;21(12):2237-46. Erratum in: J Clin Oncol. 2004 Dec 1;22(23):4863. http://dx.doi.org/10.1200/JCO.2003.10.038
23. Kris MG, Natale RB, Herbst RS, Lynch TJ Jr, Prager D, Belani CP, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA. 2003;290(16):2149-58. http://dx.doi.org/10.1001/jama.290.16.2149
24. Giaccone G, Herbst RS, Manegold C, Scagliotti G, Rosell R, Miller V, et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1. J Clin Oncol. 2004;22(5):777-84. http://dx.doi.org/10.1200/JCO.2004.08.001
25. Herbst RS, Giaccone G, Schiller JH, Natale RB, Miller V, Manegold C, et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-smallcell lung cancer: a phase III trial--INTACT 2. J Clin Oncol. 2004;22(5):785-94. http://dx.doi.org/10.1200/JCO.2004.07.215
26. Herbst RS, Prager D, Hermann R, Fehrenbacher L, Johnson BE, Sandler A, et al. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol. 2005;23(25):5892-9. http://dx.doi.org/10.1200/JCO.2005.02.840
27. Gatzemeier U, Pluzanska A, Szczesna A, Kaukel E, Roubec J, De Rosa F, et al. Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial. J Clin Oncol. 2007;25(12):1545-52. http://dx.doi.org/10.1200/JCO.2005.05.1474
28. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005;353(2):123-32. http://dx.doi.org/10.1056/NEJMoa050753
29. Jänne PA, Gurubhagavatula S, Yeap BY, Lucca J, Ostler P, Skarin AT, et al. Outcomes of patients with advanced non-small cell lung cancer treated with gefitinib (ZD1839, “Iressa”) on an expanded access study. Lung Cancer. 2004;44(2):221-30. http://dx.doi.org/10.1016/j.lungcan.2003.12.014
30. Thatcher N, Chang A, Parikh P, Rodrigues Pereira J, Ciuleanu T, von Pawel J, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet. 2005;366(9496):1527-37. http://dx.doi.org/10.1016/S0140-6736(05)67625-8
31. Kim ES, Hirsh V, Mok T, Socinski MA, Gervais R, Wu YL, et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet. 2008;372(9652):1809-18. http://dx.doi.org/10.1016/S0140-6736(08)61758-4
32. Hanna N, Shepherd FA, Fossella FV, Pereira JR, De Marinis F, von Pawel J, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol. 2004;22(9):1589-97. http://dx.doi.org/10.1200/JCO.2004.08.163
33. Fukui T, Mitsudomi T. Mutations in the epidermal growth factor receptor gene and effects of EGFR-tyrosine kinase inhibitors on lung cancers. Gen Thorac Cardiovasc Surg. 2008;56(3):97-103. http://dx.doi.org/10.1007/s11748-007-0193-8
34. Greulich H, Chen TH, Feng W, Jänne PA, Alvarez JV, Zappaterra M, et al. Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants. PLoS Med. 2005;2(11):e313. http://dx.doi.org/10.1371/journal. pmed.0020313
35. Okabe T, Okamoto I, Tamura K, Terashima M, Yoshida T, Satoh T, et al. Differential constitutive activation of the epidermal growth factor receptor in non-small cell lung cancer cells bearing EGFR gene mutation and amplification. Cancer Res. 2007;67(5):2046-53. http://dx.doi.org/10.1158/0008-5472.CAN-06-3339
36. Akca H, Tani M, Hishida T, Matsumoto S, Yokota J. Activation of the AKT and STAT3 pathways and prolonged survival by a mutant EGFR in human lung cancer cells. Lung Cancer. 2006;54(1):25-33. http://dx.doi.org/10.1016/j.lungcan.2006.06.007
37. Pontes LDEB, Bacchi CE, Queiroga EM, Piha T, Miranda PA, Freire S, et al. EGFR mutation screening in non-small cell lung cancer: results from an access program in Brazil. J Clin Oncol. 2014;32:5s (suppl; abstr 1526).
38. Bacchi CE, Ciol H, Queiroga EM, Benine LC, Silva LH, Ojopi EB, et al. Epidermal growth factor receptor and KRAS mutations in Brazilian lung cancer patients. Clinics (Sao Paulo). 2012;67(5): 419–24. http://dx.doi.org/10.6061/clinics/2012(05)03
39. Li D, Ambrogio L, Shimamura T, Kubo S, Takahashi M, Chirieac LR, et al. BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene. 2008;27(34):4702-11. http://dx.doi.org/10.1038/onc.2008.109
40. Spigel DR, Ervin TJ, Ramlau R, Daniel DB, Goldschmidt JH, Blumenschein GR, et al. Final efficacy results from OAM4558g, a randomized phase II study evaluating MetMAb or placebo in combination with erlotinib in advanced NSCLC. J Clin Oncol. 2011;29 (suppl; abstr 7505).
41. Scagliotti GV, Novello S, Schiller JH, Hirsh V, Sequist LV, Soria JC, et al. Rationale and design of MARQUEE: a phase III, randomized, double-blind study of tivantinib plus erlotinib versus placebo plus erlotinib in previously treated patients with locally advanced or metastatic, nonsquamous, non-small-cell lung cancer. Clin Lung Cancer. 2012;13(5):391-5. http://dx.doi.org/10.1016/j.cllc.2012.01.003
42. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361(10):947-57. http://dx.doi.org/10.1056/NEJMoa0810699
43. Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 2010;362(25):2380-8. http://dx.doi.org/10.1056/NEJMoa0909530
44. Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol. 2010;11(2):121-8. http://dx.doi.org/10.1016/S1470-2045(09)70364-X
45. Zhou C, Wu YL, Chen G, Feng J, Liu XQ, Wang C, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2011;12(8):735-42. http://dx.doi.org/10.1016/S1470-2045(11)70184-X
46. Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012;13(3):239-46. http://dx.doi.org/10.1016/S1470-2045(11)70393-X
47. Sequist LV, Yang JC, Yamamoto N, O’Byrne K, Hirsh V, Mok T, et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol. 2013;31(27):3327-34. http://dx.doi.org/10.1200/JCO.2012.44.2806
48. Wu YL, Zhou C, Hu CP, Feng J, Lu S, Huang Y, et al. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-smallcell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. Lancet Oncol. 2014;15(2):213-22. http://dx.doi.org/10.1016/S1470-2045(13)70604-1
49. Yang JC, Wu YL, Schuler M, Sebastian M, Popat S, Yamamoto N, et al. Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. Lancet Oncol. 2015;16(2):141-51. http://dx.doi.org/10.1016/S1470-2045(14)71173-8
50. Fukuoka M, Wu YL, Thongprasert S, Sunpaweravong P, Leong SS, Sriuranpong V, et al. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol. 2011;29(21):2866-74. http://dx.doi.org/10.1200/JCO.2010.33.4235
51. Rosell R, Moran T, Queralt C, Porta R, Cardenal F, Camps C, et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med. 2009;361(10):958-67. http://dx.doi.org/10.1056/NEJMoa0904554
52. Lacouture ME, Anadkat MJ, Bensadoun RJ, Bryce J, Chan A, Epstein JB, et al. Clinical practice guidelines for the prevention and treatment of EGFR inhibitorassociated dermatologic toxicities. Support Care Cancer. 2011;19(8):1079-95. http://dx.doi.org/10.1007/s00520-011-1197-6
53. Berger LA, Riesenberg H, Bokemeyer C, Atanackovic D. CNS metastases in non-small-cell lung cancer: current role of EGFR-TKI therapy and future perspectives. Lung Cancer. 2013;80(3):242-8. http://dx.doi.org/10.1016/j.lungcan.2013.02.004
54. Park K, Ahn M, Yu C, Kim S, Lin M, Sriuranpong V, et al. ASPIRATION: first-line erlotinib (E) until and beyond RECIST progression (PD) in Asian patients (pts) with EGFR mutation-positive (mut+) NSCLC. Ann Oncol. 2014;25 (suppl 4):iv426-iv427. http://dx.doi.org/10.1093/annonc/mdu349.2
55. Cataldo VD, Gibbons DL, Pérez-Soler R, Quintás-Cardama A. Treatment of non–small-cell lung cancer with erlotinib or gefitinib. N Engl J Med. 2011;364(10):947-55. http://dx.doi.org/10.1056/NEJMct0807960
56. Barlesi F, Blons H, Beau-Faller M, Rouquette I, Ouafik L, Mosser J, et al. Biomarkers (BM) France: Results of routine EGFR, HER2, KRAS, BRAF, PI3KCA mutations detection and EML4-ALK gene fusion assessment on the first 10,000 non-small cell lung cancer (NSCLC) patients (pts). J Clin Oncol. 2013;31 (suppl; abstr 8000).
57. Lindeman NI, Cagle PT, Beasley MB, Chitale DA, Dacic S, Giaccone G, et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. J Thorac Oncol. 2013;8(7):823-59. http://dx.doi.org/10.1097/JTO.0b013e318290868f
58. Maheswaran S, Sequist LV, Nagrath S, Ulkus L, Brannigan B, Collura CV, et al. Detection of mutations in EGFR in circulating lung-cancer cells. N Engl J Med. 2008;359(4):366-77. http://dx.doi.org/10.1056/NEJMoa0800668
59. Sanger F, Nicklen S, Coulson AR. DNA sequencing with chain-terminating inhibitors. Proc Natl Acad Sci U S A. 1977;74(12):5463-7. http://dx.doi.org/10.1073/pnas.74.12.5463
60. Pao W, Ladanyi M. Epidermal growth factor receptor mutation testing in lung cancer: searching for the ideal method. Clin Cancer Res. 2007;13(17):4954-5. http://dx.doi.org/10.1158/1078-0432.CCR-07-1387
61. Kimura H, Kasahara K, Kawaishi M, Kunitoh H, Tamura T, Holloway B, et al. Detection of epidermal growth factor receptor mutations in serum as a predictor of the response to gefitinib in patients with non-small-cell lung cancer. Clin Cancer Res. 2006;12(13):3915-21. http://dx.doi.org/10.1158/1078-0432.CCR-05-2324
62. Leighl NB, Rekhtman N, Biermann WA, Huang J, Mino-Kenudson M, Ramalingam SS, et al. Molecular testing for selection of patients with lung cancer for Epidermal Growth Factor Receptor and Anaplastic Lymphoma Kinase tyrosine kinase inhibitors: American Society of Clinical Oncology endorsement of the College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology guideline. J Clin Oncol. 2014;32(32):3673-9. http://dx.doi.org/10.1200/JCO.2014.57.3055
63. Jian G, Songwen Z, Ling Z, Qinfang D, Jie Z, Liang T, et al. Prediction of epidermal growth factor receptor mutations in the plasma/pleural effusion to efficacy of gefitinib treatment in advanced non-small cell lung cancer. J Cancer Res Clin Oncol. 2010;136(9):1341-7. http://dx.doi.org/10.1007/s00432-010-0785-z
64. Asano H, Toyooka S, Tokumo M, Ichimura K, Aoe K, Ito S, et al. Detection of EGFR gene mutation in lung cancer by mutant-enriched polymerase chain reaction assay. Clin Cancer Res. 2006;12(1):43-8. http://dx.doi.org/10.1158/1078-0432.CCR-05-0934
65. Pan Q, Pao W, Ladanyi M. Rapid polymerase chain reaction-based detection of epidermal growth factor receptor gene mutations in lung adenocarcinomas. J Mol Diagn. 2005;7(3):396-403. http://dx.doi.org/10.1016/S1525-1578(10)60569-7
66. Yatabe Y, Hida T, Horio Y, Kosaka T, Takahashi T, Mitsudomi T. A rapid, sensitive assay to detect EGFR mutation in small biopsy specimens from lung cancer. J Mol Diagn. 2006;8(3):335-41. http://dx.doi.org/10.2353/jmoldx.2006.050104
67. Chin TM, Anuar D, Soo R, Salto-Tellez M, Li WQ, Ahmad B, et al. Detection of epidermal growth factor receptor variations by partially denaturing HPLC. Clin Chem. 2007;53(1):62-70. http://dx.doi.org/10.1373/clinchem.2006.074831
68. Simonetti S, Molina MA, Queralt C, de Aguirre I, Mayo C, Bertran-Alamillo J, et al. Detection of EGFR mutations with mutation-specific antibodies in stage IV non-smallcell lung cancer. J Transl Med. 2010;8:135. http://dx.doi.org/10.1186/1479-5876-8-135
69. Travis WD, Brambilla E, Noguchi M, Nicholson AG, Geisinger KR, Yatabe Y, et al. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol. 2011;6(2):244-85. http://dx.doi.org/10.1097/JTO.0b013e318206a221
70. Shaw AT, Kim DW, Nakagawa K, Seto T, Crinó L, Ahn MJ, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med. 2013;368(25):2385-94. http://dx.doi.org/10.1056/NEJMoa1214886
71. Weir BA, Woo MS, Getz G, Perner S, Ding L, Beroukhim R, et al. Characterizing the cancer genome in lung adenocarcinoma. Nature. 2007;450(7171):893-8. http://dx.doi.org/10.1038/nature06358
72. Cancer Genome Atlas Research Network. Comprehensive molecular profiling of lung adenocarcinoma. Nature. 2014;511(7511):543-50. Erratum in: Nature. 2014;514(7521):262. http://dx.doi.org/10.1038/nature13385
73. Garassino MC, Martelli O, Broggini M, Farina G, Veronese S, Rulli E, et al. Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial. Lancet Oncol. 2013;14(10):981-8. http://dx.doi.org/10.1016/S1470-2045(13)70310-3
74. Jackman D, Pao W, Riely GJ, Engelman JA, Kris MG, Jänne PA, et al. Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. J Clin Oncol. 2010;28(2):357-60. http://dx.doi.org/10.1200/JCO.2009.24.7049
75. Cappuzzo F, Ciuleanu T, Stelmakh L, Cicenas S, Szczésna A, Juhász E, et al. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol. 2010;11(6):521-9. http://dx.doi.org/10.1016/S1470-2045(10)70112-1